Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses S Elisaf

Showing results (41-50 of 198) with videos related to

Pageof 20
Sort By:
Archives of Toxicology|May 12, 2016
The current role of thiazolidinediones in diabetes managementChristos V Rizos, Anastazia Kei, Moses S Elisaf
Journal of Geriatric Cardiology : JGC|May 12, 2016
Thiazide-associated hyponatremia in the elderly: what the clinician needs to knowGeorge Liamis, Theodosios D Filippatos, Moses S Elisaf
Current Medical Research and Opinion|July 24, 2014
Reaching low density lipoprotein cholesterol targetsChristos V Rizos, Fotios Barkas, Moses S Elisaf
Expert Opinion on Pharmacotherapy|May 26, 2010
Current role of statins in the treatment of essential hypertensionMichael S Kostapanos, Haralampos J Milionis, Moses S Elisaf
Current Drug Safety|March 9, 2019
Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case ReportAndromachi Makri, Matilda Florentin, Moses S Elisaf, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 16, 2017
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetesChristos V Rizos, Theodosios D Filippatos, Moses S Elisaf
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 11, 2002
The hyponatremic patient: a systematic approach to laboratory diagnosisHaralampos J Milionis, George L Liamis, Moses S Elisaf
The Review of Diabetic Studies : RDS|July 16, 2015
Adverse Effects of GLP-1 Receptor AgonistsTheodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisaf
The Annals of Pharmacotherapy|May 30, 2003
Possible cefotaxime-induced Stevens-Johnson syndromeEvagelos N Liberopoulos, George L Liamis, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Pageof 20

Showing results (41-50 of 198) with videos related to

Sort By:
Pageof 20
Archives of Toxicology|May 12, 2016
The current role of thiazolidinediones in diabetes managementChristos V Rizos, Anastazia Kei, Moses S Elisaf
Journal of Geriatric Cardiology : JGC|May 12, 2016
Thiazide-associated hyponatremia in the elderly: what the clinician needs to knowGeorge Liamis, Theodosios D Filippatos, Moses S Elisaf
Current Medical Research and Opinion|July 24, 2014
Reaching low density lipoprotein cholesterol targetsChristos V Rizos, Fotios Barkas, Moses S Elisaf
Expert Opinion on Pharmacotherapy|May 26, 2010
Current role of statins in the treatment of essential hypertensionMichael S Kostapanos, Haralampos J Milionis, Moses S Elisaf
Current Drug Safety|March 9, 2019
Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case ReportAndromachi Makri, Matilda Florentin, Moses S Elisaf, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 16, 2017
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetesChristos V Rizos, Theodosios D Filippatos, Moses S Elisaf
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 11, 2002
The hyponatremic patient: a systematic approach to laboratory diagnosisHaralampos J Milionis, George L Liamis, Moses S Elisaf
The Review of Diabetic Studies : RDS|July 16, 2015
Adverse Effects of GLP-1 Receptor AgonistsTheodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisaf
The Annals of Pharmacotherapy|May 30, 2003
Possible cefotaxime-induced Stevens-Johnson syndromeEvagelos N Liberopoulos, George L Liamis, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Pageof 20